MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2020.11.010

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2020

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.

Robert Caroline, Hwu Wen-Jen, Hamid Omid, Ribas Antoni, Weber Jeffrey S, Daud Adil I, Hodi F Stephen, Wolchok Jedd D, Mitchell Tara C, Hersey Peter, Dronca Roxana, Joseph Richard W, Boutros Celine, Min Le, Long Georgina V, Schachter Jacob, Puzanov Igor, Dummer Reinhard, Lin Jianxin, Ibrahim Nageatte, Diede Scott J, Carlino Matteo S, Joshua Anthony M

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

Long-term safety of pembrolizumab in melanoma was analyzed in KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006.

PATIENTS AND

METHODS

Analysis involved patients who received ≥1 pembrolizumab dose. Lead-time bias was addressed via landmark analyses in patients who were progression-free before day 147.

RESULTS

Adverse events (AEs) were analyzed for 1567 patients (median follow-up, 42.4 months). Most AEs were mild/moderate; grade 3/4 treatment-related AEs occurred in 17.7% of patients. Two pembrolizumab-related deaths occurred. Any-grade immune-mediated AEs (imAEs) occurred in 23.0%, most commonly hypothyroidism (9.1%), pneumonitis (3.3%), and hyperthyroidism (3.0%); grade 3/4 imAEs occurred in 6.9% of patients. Most imAEs occurred within 16 weeks of treatment. In landmark analysis, patients who did (n = 79) versus did not (n = 384) develop imAEs had similar objective response rates (ORRs) (64.6% versus 63.0%); median time to response (TTR), 5.6 months for both; median duration of response (DOR), 20.0 versus 25.3 months; median progression-free survival (PFS), 17.0 versus 17.7 months; median overall survival (OS), not reached (NR) versus 43 months (p = 0.1104). Patients who did (n = 17) versus did not (n = 62) receive systemic corticosteroids had similar ORRs (70.6% vs. 62.9%) and median TTR (6.4 vs. 5.6 months) but numerically shorter median PFS (9.9 vs. 17.0 months); median DOR, 14.2 months versus NR; median OS, NR for both.

CONCLUSIONS

These results enhance the knowledge base for pembrolizumab in advanced melanoma, with no new toxicity signals after lengthy follow-up of a large population. In landmark analyses, pembrolizumab efficacy was similar regardless of imAEs or systemic corticosteroid use.

CLINICAL TRIAL REGISTRY: NCT01295827, NCT01704287, NCT01866319.

Для цитирования: Robert Caroline, Hwu Wen-Jen, Hamid Omid, Ribas Antoni, Weber Jeffrey S, Daud Adil I, Hodi F Stephen, Wolchok Jedd D, Mitchell Tara C, Hersey Peter, Dronca Roxana, Joseph Richard W, Boutros Celine, Min Le, Long Georgina V, Schachter Jacob, Puzanov Igor, Dummer Reinhard, Lin Jianxin, Ibrahim Nageatte, Diede Scott J, Carlino Matteo S, Joshua Anthony M. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.. European journal of cancer (Oxford, England : 1990). 2020. DOI: 10.1016/j.ejca.2020.11.010.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.